​

Geron (GERN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GERN Stock Forecast

Geron (GERN) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $6.83, with a high of $8.00 and a low of $5.50. This represents a 136.33% increase from the last price of $2.89.

$2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $6.83 Low: $5.5 Last Closed Price: $2.89

GERN Stock Rating

Geron stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

GERN Forecast vs Benchmarks

TypeNameUpside
StockGeron136.33%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-18
Avg Price Target-$8.00$6.00
Last Closing Price$2.89$2.89$2.89
Upside/Downside-176.82%107.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2545---9
Dec, 2455---10
Nov, 24552--12
Oct, 24452--11
Sep, 24352--10
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Emily BodnarH.C. Wainwright$8.00$4.2488.68%176.82%
Oct 22, 2024Kalpit PatelB.Riley Financial$5.50$3.9539.24%90.31%
Sep 09, 2024Faisal KhurshidLeerink Partners$7.00$4.2564.71%142.21%
Jun 10, 2024Corinne JenkinsGoldman Sachs$6.00$4.9521.21%107.61%
Jun 10, 2024Stephen WilleyStifel Nicolaus$7.00$4.5952.51%142.21%
Apr 30, 2024Joel BeattyRobert W. Baird$4.50$4.148.70%55.71%
Mar 15, 2024Gil BlumNeedham$5.00$3.3648.81%73.01%
Mar 15, 2024Corinne JenkinsGoldman Sachs$5.00$3.3648.81%73.01%
Jan 09, 2023Needham$4.00$2.7943.37%38.41%
Jan 04, 2023Wedbush$6.00$3.1590.48%107.61%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024H.C. WainwrightBuyinitialise
Oct 03, 2024Goldman SachsBuyBuyhold
Aug 09, 2024B. RileyBuyBuyhold
Jun 10, 2024Goldman SachsBuyBuyhold
Jun 10, 2024WedbushBuyBuyhold
Jun 10, 2024BarclaysOverweightinitialise
Jun 07, 2024Cowen & Co.BuyBuyhold
Apr 29, 2024WedbushBuyBuyhold
Sep 12, 2023Goldman SachsNeutralBuyupgrade
Sep 12, 2023Seaport GlobalNeutralinitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.28$-0.37$-0.37$-0.32-----
Avg Forecast$-0.26$-0.34$-0.38$-0.34$-0.25$-0.06$0.18$0.43$0.81
High Forecast$-0.41$-0.52$-0.64$-0.35$-0.34$-0.08$0.06$0.26$0.65
Low Forecast$-0.13$-0.17$-0.29$-0.32$-0.11$-0.05$0.26$0.59$1.01
Surprise %7.69%8.82%-2.63%-5.88%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$253.00K$1.39M$596.00K$237.00K-----
Avg Forecast$243.67K$424.20K$604.33K$293.17K$90.83M$294.65M$539.51M$787.06M$1.16B
High Forecast$151.52K$263.77K$486.81K$209.41K$66.34M$245.65M$535.19M$784.45M$986.66M
Low Forecast$347.02K$604.14K$920.03K$366.46K$174.00M$343.07M$543.83M$789.67M$1.39B
Surprise %3.83%228.38%-1.38%-19.16%-----

Net Income Forecast

$-300M $-120M $60M $240M $420M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-75.61M$-120.95M$-141.03M$-184.13M-----
Avg Forecast$-149.32M$-191.74M$-111.07M$-184.13M$-127.87M$-37.96M$97.05M$253.38M$459.76M
High Forecast$-231.66M$-297.47M$-133.28M$-220.95M$-194.58M$-46.21M$35.27M$149.55M$371.66M
Low Forecast$-75.91M$-97.47M$-88.85M$-147.30M$-61.16M$-29.72M$148.12M$334.71M$577.78M
Surprise %-49.36%-36.92%26.98%------

GERN Forecast FAQ

Is Geron stock a buy?

Geron stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Geron is a favorable investment for most analysts.

What is Geron's price target?

Geron's price target, set by 7 Wall Street analysts, averages $6.83 over the next 12 months. The price target range spans from $5.5 at the low end to $8 at the high end, suggesting a potential 136.33% change from the previous close price of $2.89.

How does Geron stock forecast compare to the average forecast of its sector, industry, and investment themes?

Geron stock forecast shows a 136.33% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Geron over the past three months?

  • January 2025: 44.44% Strong Buy, 55.56% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 41.67% Strong Buy, 41.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Geron’s EPS forecast?

Geron's average annual EPS forecast for its fiscal year ending in December is -0.25 for 2024, a -21.88% decrease from the reported $-0.32 in 2023. The prediction for 2025 is $-0.06, $0.18 for 2026, $0.43 for 2027, and $0.81 for 2028.

What is Geron’s revenue forecast?

Geron's average annual revenue forecast for its fiscal year ending in December is $90.83M for 2024, a 38226.10% increase from the reported $237K in 2023. The forecast for 2025 is $294.65M, $539.51M for 2026, $787.06M for 2027, and $1.16B for 2028.

What is Geron’s net income forecast?

For its fiscal year ending in December, Geron's average annual net income forecast is $-128M for 2024, reflecting a -30.55% decrease from the reported $-184M in 2023. The projection for 2025 is $-37.964M, $97.05M for 2026, $253.38M for 2027, and $459.76M for 2028.